15 Prostate Cancer Clinical Trials in New Haven, CT (2026)

Q: How do I join a clinical trial in New Haven?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the New Haven research site will contact you.

Recruiting Prostate Cancer Studies in New Haven

NCT03151629Recruiting

International Registry for Men With Advanced Prostate Cancer (IRONMAN)

Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cance...

New Haven, CT5,000 participantsProstate Cancer Clinical Trials Consortium

View Study Details

NCT06925737Recruiting

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-...

New Haven, CTPHASE31,440 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06136624Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) ...

New Haven, CTPHASE31,310 participantsMerck Sharp & Dohme LLC

View Study Details

NCT04221542Recruiting

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate pr...

New Haven, CTPHASE1479 participantsAmgen

View Study Details

NCT03972657Recruiting

A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

The main purpose of this study is to determine the safety, tolerability (how your body reacts to the drug) and effectiveness (ability to treat your cancer) of REGN5678 alone, or in combination with ce...

New Haven, CTPHASE1345 participantsRegeneron Pharmaceuticals

View Study Details

NCT05519449Recruiting

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults...

New Haven, CTPHASE1272 participantsJanux Therapeutics

View Study Details

NCT05125016Recruiting

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer

This study is researching an investigational drug called REGN4336. Some participants may receive additional investigational drugs in combination with REGN4336. These additional drugs include REGN5678,...

New Haven, CTPHASE1228 participantsRegeneron Pharmaceuticals

View Study Details

NCT05800665Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also ide...

New Haven, CTPHASE1210 participantsGenentech, Inc.

View Study Details

NCT06800313Recruiting

A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Assessment of the safety and efficacy of HLD-0915 as monotherapy in patients with metastatic castration resistant prostate cancer (mCRPC) that have progressed on prior systemic therapies, once a recom...

New Haven, CTPHASE1190 participantsHalda Therapeutics OpCo, Inc.

View Study Details

NCT06991556Recruiting

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen...

New Haven, CTPHASE2150 participantsNovartis Pharmaceuticals

View Study Details

NCT06990880Recruiting

A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer

The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose e...

New Haven, CTPHASE185 participantsGlaxoSmithKline

View Study Details

NCT06842498Recruiting

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in th...

New Haven, CTPHASE275 participantsKyntra Bio

View Study Details

NCT06111781Recruiting

The SUGAR Study; SBRT and Relugolix) for Prostate Cancer

The goal of this clinical trial is to measure the toxicity and effectiveness of the following treatments for cFIR/cgUIR prostate cancer patients. Stereotactic body radiotherapy (SBRT) alone or Stereo...

New Haven, CTPHASE260 participantsYale University

View Study Details

NCT06457919Recruiting

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people ...

New Haven, CTPHASE150 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06100705Recruiting

Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

This is an open-label, single-arm phase II study of bipolar androgen therapy (BAT) given in addition with standard of care Sipuleucel-T to determine the interferon (IFN) gamma Enzyme-linked Immunospot...

New Haven, CTPHASE226 participantsYale University

View Study Details

About Prostate Cancer Clinical Trials in New Haven

Prostate cancer develops in the prostate gland and is one of the most common cancers in men. Many prostate cancers grow slowly, but some can be aggressive. Treatment options range from active surveillance to surgery, radiation, and hormone therapy.

There are currently 15 prostate cancer clinical trials recruiting participants in New Haven, CT. These studies are seeking a combined 9,920 participants. Research is being sponsored by Prostate Cancer Clinical Trials Consortium, Merck Sharp & Dohme LLC, Amgen and 9 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Prostate Cancer Clinical Trials in New Haven — FAQ

Are there prostate cancer clinical trials in New Haven?

Yes, there are 15 prostate cancer clinical trials currently recruiting in New Haven, CT. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New Haven?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New Haven research site will contact you about next steps.

Are clinical trials in New Haven free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New Haven studies also compensate for your time and travel.

What prostate cancer treatments are being tested?

The 15 active trials in New Haven are testing new therapies including novel drugs, biologics, and treatment approaches for prostate cancer.

Data updated July 17, 2026 from ClinicalTrials.gov